Abstract
MSP001 is a newly synthesized piperidine analog of the lead antihypertensive compound MS23 that dually targets cAMP-specific type 4 phosphodiesterase and L-type calcium channels. We validated an analytical protocol for MSP001 in rat plasma using high performance liquid chromatographic method. A C18 column and a phosphate/acetonitrile buffer were used to perform the chromatographic separation. UV detection was carried out at 307 nm, a wavelength at which an absorption peak was detected for this group of compounds. The calibration curve for MSP001 was linear in the range from 25 to 10,000 ng/ml. The limit of quantification (LOQ) was 25 ng/ml. The results demonstrate that this method has high linearity (R = 0.99995), compound specificity, and acceptable precision/accuracy. The protocol is suitable for in vivo pharmacokinetic studies on the compound.
Original language | English (US) |
---|---|
Pages (from-to) | 607-612 |
Number of pages | 6 |
Journal | Journal of Pharmaceutical and Biomedical Analysis |
Volume | 42 |
Issue number | 5 |
DOIs | |
State | Published - Nov 16 2006 |
Keywords
- Antihypertensive
- Dual action
- MS23
- MSP001
- Validation
ASJC Scopus subject areas
- Analytical Chemistry
- Pharmaceutical Science
- Drug Discovery
- Spectroscopy
- Clinical Biochemistry